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Abstract
Background: New biomarkers are needed to assess the severity of necrotizing soft tissue infection (NSTI) at an
early stage and to individualize treatment strategies. We assessed pentraxin-3 (PTX3) as a marker of disease severity
and risk of death in patients with NSTI.
Methods: We conducted a prospective, observational study in the intensive care unit at Copenhagen University
Hospital, where treatment of NSTI is centralized at a national level. We compared PTX3, procalcitonin and C-reactive
protein in septic shock versus nonshock patients and in amputated versus nonamputated patients using the
Mann-Whitney U test. The prognostic value of the markers for 180-day mortality was assessed using Cox
regression analyses.
Results: Patients with NSTI (n = 135) were included over 25 months with up to 2.5-year follow-up; 71 % had
septic shock, amputation was undertaken in 20 % and the 180-day mortality was 27 %. Baseline plasma PTX3
level was significantly higher in patients with septic shock (67.3 versus 24.6 ng/mL, p < 0.0001) and in patients who
underwent amputation (118.6 versus 43.6 ng/mL, p = 0.019). No significant differences in baseline procalcitonin or
C-reactive protein levels were found according to amputation (25.2 versus 7.0 μg/L, p = 0.060 and 202 versus 225 mg/L,
p = 0.123), respectively. Baseline PTX3 level above the median was associated with death (p = 0.009, log-rank test) and the
univariate Cox regression analysis revealed a significant association between PTX3 level upon admission and
180-day mortality (hazard ratio 2.60 (95 % confidence interval 1.28–5.29), p = 0.008). When adjusted for age,
sex, chronic disease and Simplified Acute Physiology Score II, no significant association was found.
Conclusions: High PTX3 level is associated with septic shock, amputation and risk of death in patients with
NSTI, but it is not an independent predictor of 180-day mortality in this patient group.
Trial registration: ClinicalTrials.gov Identifier: NCT02180906. Date of registration: June 29, 2014.
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Background
Necrotizing soft tissue infection (NSTI) is a bacterial in-
fection of any layer within the soft tissue compartments
associated with necrosis. The condition is often accom-
panied by septic shock, and the extensive inflammatory
response is thought to be a primary cause of mortality
[1]. Delay of surgery has been shown to be an inde-
pendent risk factor for mortality, and studies stress
the importance of surgical debridement and early amputa-
tion of infected limbs [2–5]. However, an aggressive
surgical approach increases the risk of severe disabil-
ity and impaired quality of life. Moreover, surgical de-
cisions are often based on the surgeon’s experience
and practice guidelines.
Biomarkers may provide therapeutic guidance and
prognostication, and thereby improve decision-making
in patients with NSTI. To date, C-reactive protein (CRP)
and procalcitonin (PCT) have been used to monitor in-
fectious disease progression in the intensive care unit
(ICU). However, the literature investigating the value of
biomarkers in patients with NSTI is sparse and often
limited by retrospective study designs [6–8]. Due to the
low incidence, the knowledge and evidence from septic
patients are extrapolated to those with NSTI, even
though the immunological reaction may differ because
of the extensive tissue damage and different pathogen-
esis. It would be desirable if biomarkers could be used to
identify patients with NSTI at high risk of death, as
more aggressive treatment could then be undertaken in
this subgroup while extensive surgery could be avoided
in low-risk patients.
Pentraxin-3 (PTX3) is a multifunctional pattern-
recognition molecule released at the onset of inflamma-
tion as part of the innate immune system by activating
the classical and lectin complement pathways through
specific recognition of the C1q, mannose-binding lectin,
ficolin-1 and ficolin-2 subunits [9–13]. A high PTX3
level is associated with disease severity and mortality in
patients with myocardial infarction [14–16], ischemic
stroke [17], cancer [18, 19], acute respiratory distress
syndrome [20] and sepsis [21–23]. PTX3 is closely re-
lated to CRP as both are members of the pentraxin fam-
ily of proteins, and PTX3 is central to the antimicrobial
responses and in the clearance of cellular debris.
As PTX3 is produced locally by various cells, including
monocytes, neutrophils and endothelial cells in response
to tumor necrosis factor and bacterial products, it is rea-
sonable to consider PTX3 as a marker of local inflamma-
tion detected by direct release to the blood stream [24]. In
contrast, CRP is produced in the liver in response to
locally induced interleukin-6 [25, 26], while the expression
and synthesis of PCT in response to inflammatory stimuli
seems to be more ubiquitous [27]. Despite the promising
role of PTX3 in the risk stratification of various infections
and inflammatory conditions, the prognostic relevance in
patients with NSTI remains to be evaluated.
The aim of this study was to assess plasma PTX3 as a
marker of disease severity and risk of death in patients
with NSTI.
Methods
Study design and setting
This prospective, observational study was conducted
during February 2013 to March 2015 at Copenhagen
University Hospital (Rigshospitalet) as a substudy of the
ongoing European INFECT project (ClinicalTrials.gov
Identifier: NCT01790698). The protocol of this study is
described in greater detail elsewhere [28] and registered at
ClinicalTrials.gov (NCT02180906). In Denmark (popula-
tion 5.6 million) the treatment of NSTI is centralized at a




Patients were included if they had been: (1) diagnosed
with NSTI based on surgical findings with necrosis en-
gaging any layers of the soft tissue compartments; (2)
aged ≥18 years; and (3) had either been admitted to the
ICU or undergone surgery for NSTI at Rigshospitalet.
Patients were excluded if the NSTI diagnosis could not
be confirmed during surgery. For the majority of pa-
tients, the first operation had been at a primary hospital
before the transfer to our center.
Control patients
Control patients were eligible for inclusion if they were:
(1) undergoing elective orthopedic surgery at Rigshospi-
talet; and (2) were aged ≥18 years. Patients with ongoing
infection or inflammatory conditions were excluded. We
included 65 control patients, matched for age and sex
during September 2014 to March 2015.
Data collection
Clinical data
We obtained data from electronic records on age, sex,
body mass index, chronic disease (diabetes, liver cirrhosis,
chronic kidney disease, cardiovascular disease, chronic ob-
structive pulmonary disease, peripheral vascular disease,
immune deficiency, malignancy, rheumatoid disease), pri-
mary site of infection, microorganism, biochemistry, ICU
scoring systems and treatment. Vital status and time of
death, if relevant, were extracted from the hospital data-
base linked to the Danish Civil Registration System. The
criterion for amputation was based on the surgeon’s
clinical evaluation of the infected body part and per-
formed as a final method to obtain infection control. No
strict protocol for amputation was used.
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Blood sampling and processing
Blood was drawn from an arterial line into 9-mL vac-
uum tubes containing EDTA at four discrete time
points: on admission (baseline) and the following
three days between 8 a.m. and 12 a.m. For the con-
trol group, the blood samples were drawn by venous
puncture at three discrete time points: preoperatively
(baseline), 2–6 h postoperatively and the day after
surgery between 8 a.m. and 12 a.m. The blood sample
was immediately put on ice until plasma was sepa-
rated from the whole blood by centrifugation (within
40 minutes) at 3500 rpm (2400 G) for 10 minutes
and was subsequently stored at −80 °C.
Routine biochemistry and hematology
Standard blood analyses including platelet count, creatin-
ine, leucocyte count, PCT and CRP levels were performed
at the Department of Clinical Biochemistry, Rigshospitalet,
as part of routine analyses, whereas sodium, potassium,
hemoglobin, lactate, pH, base excess, pO2 and pCO2 were
measured using an ABL 725 (Radiometer, Copenhagen,
Denmark).
Enzyme-linked immunosorbent assay
Plasma PTX3 levels were determined using anti-PTX3
monoclonal antibodies in a sandwich enzyme-linked im-
munosorbent assay (ELISA) developed in the Laboratory
of Molecular Medicine, Rigshospitalet, according to pre-
viously described procedures [23, 29]. In short, microti-
ter plates (Nunc Immuno Plates, F384 Maxisorp) were
coated with 2 μg/mL mouse monoclonal anti-PTX3 anti-
body (clone PTX-66) produced inhouse [23], diluted in
phosphate-buffered saline + 0.05 % Tween-20 (PBS-T),
and incubated overnight. The plasma samples were
diluted with sample buffer (1:20) in triplicates and
incubated for 3 h. The biotinylated anti-PTX3 detec-
tion antibody (clone PTX3-20) was diluted (1 μg/mL), ap-
plied to the wells and incubated overnight. Secondary
streptavidin-horseradish peroxidase conjugate was applied
for 2 h. The plates were developed with OPD substrate
and hydrogen peroxide. The optical density was measured
at 490 nm with an ELISA reader. Inhouse-produced bio-
logically active recombinant PTX3 was used as a calibra-
tor. The sensitivity of the PTX3 assay in plasma has been
estimated to be 1.5 ng/mL with an intra-assay variation of
5 % and interassay variation of 10 %.
Outcome measures
Our primary analysis focused on the association be-
tween baseline PTX3 level and disease severity by
comparing plasma PTX3 level in NSTI patients with
and without septic shock upon admission to our
center. This comparison was performed due to an
expected higher mortality rate in patients with septic
shock, thereby making it a clinically relevant stratification.
Septic shock was defined according to the criteria of
Bone et al. [30].
Secondary analyses compared PTX3 level during the
following 3 days between nonshock patients versus
patients with septic shock, amputation versus no am-
putation, and NSTI patients versus control patients.
Additionally, analyses included investigation of differ-
ences in 180-day mortality and long-term mortality
up to 2.5 years between NSTI patients with high versus
low levels (dichotomization by median) of PTX3, PCT and
CRP. Patients were followed from the date of admission to
the first of the following: death or the end of the follow-up
(August 2015).
Statistical analysis
Kolmogorov-Smirnov and Shapiro-Wilk normality tests
were performed for all variables. Due to nonparametric
distribution, continuous data are reported as median
(interquartile range (IQR)). For categorical data we re-
ported absolute numbers (proportions) with the use of
χ2-test or Fisher’s exact test for comparisons. Continu-
ous data were compared at specific time points using
Mann-Whitney U test. Correlations were assessed using
the Spearman’s rank correlation test. The prognostic
value of PTX3 for long-term mortality up to 2.5 years
was investigated using the log-rank test. The prognostic
value of PTX3, PCT and CRP for 180-day mortality was
investigated using the univariate Cox analysis. For multi-
variate analysis, the Cox proportional hazards regression
model was used with adjustment for age, sex, Simplified
Acute Physiology Score II (SAPS II) and chronic disease
(yes/no). We were unable to calculate SAPS II in five pa-
tients due to missing data. These patients were excluded
from the multivariate analysis. Data from the Cox
analyses are presented as relative hazards with 95 % confi-
dence intervals (CI). Area under the curve (AUC) and
receiver operating characteristic (ROC) curves were
reported for the inflammatory biomarkers for 180-day
mortality. The optimal cutoff was identified as the value
corresponding to the maximum sum of sensitivity and
specificity.
P-values < 0.05 were considered significant. Statistical
analyses were performed using Statistical Package for
the Social Sciences 22.0 software (SPSS Inc., Chicago,
IL, USA) and GraphPad Prism 6.0 software (GraphPad
Inc., La Jolla, CA, USA).
Sample size
On the basis of previous studies using the same analysis
[23], the investigators expected a mean PTX3 level
on admission of 120 ng/mL in the nonshock group
and a mean PTX3 level of 210 ng/mL in the shock
group. Assuming a standard deviation of 100 ng/mL,
Hansen et al. Critical Care  (2016) 20:40 Page 3 of 11
detection of this difference with a statistical power of
90 % at a 5 % significance level would require inclu-
sion of 52 patients. The groups were expected to be
unequal in size (1:4); therefore we needed to include
at least 82 patients.
Ethics
The study was approved by the regional ethics committee
(H-2-2014-071) and the Danish Data Protection Agency
(J. no. 30-1282) and registered at ClinicalTrials.gov
(NCT02180906). Written informed consent was obtained
from all patients or their legal substitute.
The manuscript was prepared according to the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement [31].
Results
Of 165 patients with suspected NSTI, 162 were included
(Fig. 1). Subsequently, 27 patients were excluded because
the NSTI diagnosis could not be verified during surgery.
Thus, the study population consisted of 135 NSTI pa-
tients with a median age of 61 years (range, 52–69);
71 % (n = 96 (95 % CI, 63–78)) had septic shock, ampu-
tation was undertaken in 20 % (n = 27 (95 % CI, 14–28))
and the 180-day mortality was 27 % (n = 36 (95 % CI,
20–35)) (Tables 1 and 2).
Association between pentraxin-3 and disease severity
Baseline PTX3 level was significantly higher in patients
with septic shock (67.3 (IQR, 28.8–213.5) versus 24.6
(IQR, 10.7–58.0) ng/mL, p < 0.0001) (Fig. 2a). Moreover,
baseline PTX3 level was significantly higher in patients
who underwent amputation during the first 7 days in
the ICU (118.6 (IQR, 42.4–219.6) versus 43.6 (IQR,
15.5–153.1) ng/mL, p = 0.019) (Fig. 2b) and significantly
higher in patients who died within the first 180 days
after admission (124.3 (IQR, 43.1–210.8) versus 40.0
(IQR, 14.6–134.9) ng/mL, p = 0.005) (Fig. 2c).
In general, the PTX3 level decreased during admission
to the ICU, but it increased over the first day for those
with a fatal outcome whilst the PTX3 levels decreased in
survivors (168.3 (IQR, 44.9–324.7) versus 29.0 (IQR,
14.2–110.4) ng/mL, p < 0.0001). A similar pattern was
observed in patients who underwent amputation versus
no amputation (136.3 (IQR, 32.6–303.3) versus 32.0
(IQR, 14.7–123.2) ng/mL, p = 0.008). Patients with a
streptococcal infection had a higher baseline PTX3 level
(93.9 (IQR, 22.1–283.5) versus 44.7 (IQR, 16.5–130.3)
ng/mL, p = 0.035). No difference was observed between
mono- and polymicrobial infection (44.0 (IQR, 16.9–
169.5) versus 65.2 (IQR, 19.8–174.3) ng/mL, p = 0.346).
Lastly, the patients with NSTI had a significantly higher
baseline PTX3 level compared with control patients
Fig. 1 Flow chart of patient inclusion. NSTI Necrotizing soft tissue infection
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without infection (52.4 (IQR, 17.7–172.2) versus 2.9
(IQR, 2.0–4.5) ng/mL, p < 0.0001) (Fig. 2d).
Procalcitonin and C-reactive protein
Baseline PCT level was significantly higher in patients
with septic shock (13.6 (IQR, 2.9–37.8) versus 1.5 (IQR,
0.3–7.2) μg/L, p < 0.0001), whilst no significant difference
in baseline CRP level was observed (222 (IQR, 152–302)
versus 201 (IQR, 134–275) mg/mL, p = 0.295) (Table 2).
There were no significant differences in baseline PCT
or CRP levels according to amputation (25.2 (IQR,
1.9–78.5) versus 7.0 (IQR, 1.4–22.7) μg/L, p = 0.060
and 202 (IQR, 90–244) versus 225 (IQR, 143–307)
mg/L, p = 0.123), respectively.
PTX3 correlated with PCT (Rho = 0.64 (95 % CI,
0.52–0.73), p < 0.0001) and SAPS II (Rho = 0.45 (95 % CI,
Table 1 Baseline characteristics for the entire cohort of patients with necrotizing soft tissue infections and for the septic shock and








Age, years 61 (52–69) 58 (48–70) 62 (54–69) 0.426
Sex, male 84 (62) 24 (62) 60 (63) 0.917
Body mass index, kg/m2 26 (23–31) 24 (22–31) 27 (25–32) 0.017
Chronic disease
Chronic disease 86 (64) 28 (72) 58 (60) 0.213
Diabetes 30 (22) 10 (26) 20 (21) 0.543
Liver cirrhosis 5 (4) 1 (3) 4 (4) 0.655
Chronic kidney disease 12 (9) 6 (15) 6 (6) 0.104
Cardiovascular disease 58 (43) 21 (54) 37 (39) 0.103
Chronic obstructive pulmonary disease 14 (10) 3 (8) 11 (12) 0.757
Peripheral vascular disease 20 (15) 8 (21) 12 (13) 0.235
Immune deficiency/AIDS 3 (2) 2 (5) 1 (1) 0.200
Malignancy 15 (11) 3 (8) 12 (13) 0.553
Rheumatoid disease 10 (7) 2 (5) 8 (8) 0.723
Active smoker 40 (30) 9 (23) 31 (32) 0.366
High alcohol consumptiona 19 (14) 3 (8) 16 (17) 0.191
Steroid treatment 16 (12) 4 (10) 12 (13) 0.277
Immunosuppressing drugs 12 (9) 3 (8) 9 (9) 0.281
Primary site of infection
Head/neck 21 (15) 6 (16) 15 (16) 0.972
Upper extremity 15 (11) 3 (8) 12 (13) 0.553
Lower extremity 47 (35) 13 (33) 34 (35) 0.818
Chest 5 (4) 2 (5) 3 (3) 0.626
Abdomen 11 (8) 2 (5) 9 (9) 0.510
Genital/perineum 36 (27) 13 (33) 23 (24) 0.264
Microorganism
Positive cultures 100 (74) 25 (64) 75 (78) 0.128
Polymicrobial 54 (40) 13 (33) 41 (43) 0.339
Beta-hemolytic streptococcus 46 (34) 9 (23) 37 (39) 0.120
Staphylococcus aureus 14 (10) 2 (5) 12 (13) 0.350
Anaerobes 23 (17) 9 (23) 14 (15) 0.312
Gram negative rods 25 (19) 6 (15) 19 (20) 0.632
Other 15 (11) 5 (13) 10 (10) 0.764
Values denote median (interquartile range) or number (%). Differences between the shock and nonshock group were tested using Mann-Whitney U or χ2-test/Fisher’s
exact test
aHigh alcohol consumption: >14 units of alcohol/week (women); >21 units of alcohol/week (men)
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0.30–0.58), p < 0.0001) but not with CRP (Rho = 0.15
(95 % CI, −0.03–0.32), p = 0.095). Moreover, baseline
PTX3 correlated with the Sequential Organ Failure As-
sessment (SOFA) score (Rho = 0.48 (95 % CI, 0.34–0.60),
p < 0.0001) and baseline lactate level (Rho = 0.57 (95 %
CI, 0.44–0.67), p < 0.0001). PTX3 also correlated with cre-
atinine (Rho = 0.46 (95 % CI, 0.31–0.58), p < 0.0001) and
patients receiving renal replacement therapy within the
first 7 days in the ICU had a higher baseline PTX3 level
(141.2 (IQR, 55.0–276.4) versus 34.5 (IQR, 13.0–124.3)
ng/mL, p < 0.0001).
Univariate survival analysis
During a median follow-up of 17 months (range 3–30
months), 44 patients died (32 with septic shock upon
admission). Baseline PTX3 level above the median of
52.4 ng/mL was associated with lower survival rate
(p = 0.009) (Fig. 3). Univariate survival analysis revealed
Table 2 Laboratory values, clinical scoring systems and outcomes for the entire cohort of patients with necrotizing soft tissue








Biomarker level upon admission (baseline)
Pentraxin-3, ng/mL 52.4 (17.7–172.2) 24.6 (10.7–58.0) 67.3 (28.8–213.5) <0.0001
Procalcitonin, μg/L 7.7 (1.4–28.8) 1.5 (0.3–7.2) 13.6 (2.9–37.8) <0.0001
C-reactive protein, mg/L 222 (141–298) 201 (134–275) 222 (152–302) 0.295
Biochemistry
Leukocyte count, 109/L, highest value 16.9 (10.4–23.9) 15.5 (9.7–22.7) 17.6 (12.2–24.5) 0.197
Na+, mmol/L, lowest value 136 (132–138) 136 (134–139) 135 (131–138) 0.198
K+, mmol/L, highest value 4.3 (4.0–4.9) 4.1 (3.8–4.3) 4.5 (4.1–5.2) <0.0001
Glucose, mmol/L, highest value 8.3 (7.1–11.5) 7.5 (5.8–9.9) 8.6 (7.3–12.4) 0.011
Creatinine, μmol/L, highest value 119 (77–205) 82 (58–127) 142 (82–229) 0.002
Hemoglobin, mmol/L, lowest value 5.7 (4.9–6.5) 5.7 (4.9–6.7) 5.7 (4.8.9–6.3) 0.429
pH, lowest value 7.30 (7.20–7.37) 7.35 (7.29–7.40) 7.28 (7.18–7.34) 0.006
pO2, kPa, from lowest PaO2/FiO2 ratio 13.7 (10.9–19.7) 14.4 (11,5–22.3) 12.8 (10.8–18.1) 0.137
Base excess, mmol/L, lowest value −5.5 (−9.4 to −1.8) −2.2 (−5.7 to −2.2) −6.7 (−10.9 to −2.5) 0.001
Lactate, mmol/L, highest value 1.9 (1.1–4.1) 1.0 (0.7–1.6) 2.5 (1.5–5.0) <0.0001
ICU scoring systems and treatment
SAPS IIa 45 (35–52) 35 (29–48) 46 (39–56) 0.001
SOFA (day 1)b 7 (4–10) 3 (2–5) 8 (7–10) <0.0001
LRINECc 8 (6–9) 8 (5–9) 8 (6–10) 0.103
ICU admissiond 123 (91) 28 (72) 95 (99) <0.0001
Ventilator treatment 122 (90) 27 (70) 95 (99) <0.0001
Renal replacement therapye 34 (25) 5 (13) 29 (30) 0.035
Amputation of limb or penise 27 (20) 5 (13) 22 (23) 0.184
Mortality
28-day (%, 95 % CI) 22 (16, 11–24) 8 (21, 11–36) 14 (15, 9–23) 0.398
90-day (%, 95 % CI) 31 (23, 17–31) 9 (23, 12–39) 22 (23, 16–32) 0.984
180-day (%, 95 % CI) 36 (27, 20–35) 10 (26, 14–41) 26 (27, 19–37) 0.864
Long-term up to 2.5 yearsf (%, 95 % CI) 44 (33, 25–41) 12 (31, 18–47) 32 (33, 25–43) 0.773
Values denote median (interquartile range) or number (%). Differences between the shock and non-shock group were tested using Mann-Whitney U or χ2-test/
Fisher’s exact test
aNumber of patients with missing values: n = 5 (n = 3 for nonshock; n = 2 for shock)
bNumber of patients with missing values: n = 6 (n = 3 for nonshock; n = 3 for shock)
cNumber of patients with missing values: n = 15 (n = 9 for nonshock; n = 6 for shock)
dThree patients died before admission to the ICU (n = 2 for nonshock; n = 1 for shock)
eWithin the first 7 days in the ICU
fA follow-up up to 2.5 years
CI Confidence interval, ICU Intensive care unit, LRINEC Laboratory risk indicator for necrotizing fasciitis, SAPS Simplified Acute Physiology Score, SOFA Sequential
Organ Failure Assessment
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that age, SAPS II, PTX3, PCT and CRP were significantly
associated with 180-day mortality (Table 3).
Multivariate survival analysis
When adjusted for variables specified in our protocol
[28], the association between high baseline PTX3 level
and 180-day mortality was not significant (hazard ratio
(HR) 1.05 (95 % CI, 0.47–2.35), p = 0.902) (Table 4). The
same lack of association was observed for PCT (HR 0.86
(95 % CI, 0.38–1.95), p = 0.713) and CRP (HR 0.71
(95 % CI, 0.34–1.51), p = 0.376).
Diagnostic accuracy of the inflammatory biomarkers to
predict 180-day mortality
We found low levels of sensitivity and specificity for
PTX3, PCT and CRP in the analysis of 180-day mortality
when the medians were used to define high versus low
baseline levels in plasma (Table 4).
The AUC for the ROC was low for PTX3 levels
(AUC = 0.66, p = 0.005), as was the case for PCT levels
(AUC = 0.65, p = 0.007) and CRP levels (AUC = 0.32,
p = 0.001) (Fig. 4). The AUC improved when the inflam-
matory markers were combined (AUC = 0.72, p < 0.0001).
The optimal cutoff for PTX3 was 69.8 ng/mL, identified
as the value corresponding to the maximum sum of sensi-
tivity (0.67) and specificity (0.68). When the multivariate
analysis was performed with the optimal cutoff in-
stead of the median, the risk of 180-day mortality in
patients with a high baseline PTX3 level increased
but was still not significant (HR 1.34 (95 % CI, 0.60–3.00),
p = 0.480) (Table 4).
Fig. 3 Kaplan-Meier curves of long-term mortality up to 2.5 years in
patients with necrotizing soft tissue infections stratified by median
plasma PTX3 level (>52.4 ng/mL). PTX3 Pentraxin-3
Fig. 2 Pentraxin-3 level upon admission (baseline) and for the following 3 days in a septic shock versus nonshock, b amputation versus no
amputation, c 180-day mortality and d NSTI versus control. NSTI Necrotizing soft tissue infection, PTX3 Pentraxin-3
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Discussion
We found that a high PTX3 level in patients with NSTI
at time of admission was associated with septic shock,
renal replacement therapy, amputation and risk of death.
High PCT and CRP levels were not associated with
amputation. Moreover, baseline PTX3 level correlated
with SAPS II, SOFA score, lactate and creatinine.
None of the inflammatory biomarkers was significantly as-
sociated with 180-day mortality in the multivariate
analysis and there was a low sensitivity, specificity
and AUC. However, the AUC improved when the markers
were combined.
PTX3 levels have been shown to be 1–2 ng/mL in
healthy individuals [32, 33]. In a recent study using the
same assay, healthy individuals had a median PTX3 level
of 3.5 ng/mL (range, 0.0–8.3 ng/mL) [29] compared with
2.9 ng/mL (range, 1.7–28.5 ng/mL) in the control pa-
tients in this study. The wider range might be explained
by our control patients being matched by age and sex,
thereby giving older controls with comorbidities that
contribute to increased PTX3 levels. Nevertheless, we
found significantly higher levels in the patients with
NSTI underlining PTX3 as a marker of bacterial in-
fection. However, PTX3 is not a specific marker for
bacterial infections, which is why we adjusted our
analysis for comorbidities, such as cardiovascular dis-
ease and malignancy, where high PTX3 levels have
been shown to be correlated with disease severity and
mortality [14, 15, 18, 34]. When adjusted for age, sex,
chronic disease and SAPS II, the association between
high PTX3 level upon admission and 180-day mortality
was not significant, indicating that PTX3 is not an inde-
pendent predictor of 180-day mortality. The same was ob-
served for PCT and CRP. In line with this, we did not find
a difference in mortality between septic shock versus
nonshock patients (Table 2), which could otherwise
be expected. This probably reflects that we did not
include enough patients to demonstrate a difference
in an outcome with low incidence.
It should be noted that the ROC-AUC for 180-day
mortality was low but comparable to a previous study
investigating PTX3, PCT and CRP in emergency room
patients with suspected infection [35]. It confirms that
these inflammatory biomarkers should be incorporated
as part of an overall assessment of patients with NSTI
Table 4 Multivariate analysis by Cox proportional hazards regression model and diagnostic accuracy of 180-day mortality
Markers 180-day mortality
HRa 95 % CI p Sensitivity 95 % CI Specificity 95 % CI ROC-AUC 95 % CI p
PTX3 1.05 0.47–2.35 0.902 0.69 0.53–0.82 0.56 0.50–0.60 0.66 0.56–0.76 0.005
PTX3b 1.34 0.60–3.00 0.480 0.67 0.51–0.80 0.68 0.62–0.72 . . .
PCT 0.86 0.38–1.95 0.713 0.66 0.50–0.79 0.55 0.49–0.60 0.65 0.55–0.76 0.007
CRP 0.71 0.34–1.51 0.376 0.34 0.21–0.50 0.41 0.36–0.47 0.32 0.21–0.43 0.001
PTX3 + PCT . . . . . . . 0.66 0.56–0.76 0.005
PTX3 + CRP . . . . . . . 0.72 0.61–0.82 <0.0001
PCT + CRP . . . . . . . 0.71 0.60–0.82 <0.0001
PTX3 + PCT + CRP . . . . . . . 0.72 0.62–0.83 <0.0001
Hazard ratio, sensitivity and specificity are calculated for high (above median) versus low (below median) baseline levels of the inflammatory biomarkers. Five
patients are not included in the analysis due to missing data regarding Simplified Acute Physiology Score II
aAdjusted for age, sex, Simplified Acute Physiology Score II and chronic disease (yes/no)
bPTX3 dichotomized by the optimal cutoff (69.8 ng/ml) found by the ROC curve (highest sum of sensitivity and specificity)
CRP C-reactive protein, HR Hazard ratio, PCT Procalcitonin, PTX3 Pentraxin-3, ROC-AUC Receiver operating characteristic-area under the curve, CI Confidence interval
Dots: Values cannot be given
Table 3 Cox univariate analysis for 180-day mortality
Variable n 180-day mortality
HR 95 % CI p
Age, years 135 1.04 1.01–1.07 0.005
SAPS II, point 130 1.06 1.05–1.08 <0.0001
Sex
Female 51 ref.
Male 84 1.42 0.70–2.89 0.331
Chronic disease
No 49 ref.
Yes 86 1.81 0.85–3.84 0.124
Pentraxin-3
Low ≤52.4 ng/mL ref.
High >52.4 ng/mL 2.60 1.28–5.29 0.008
Procalcitonin
Low ≤7.73 μg/L ref.
High >7.73 μg/L 2.22 1.11–4.44 0.024
C-reactive protein
Low ≤222 mg/L ref.
High >222 mg/L 0.44 0.22–0.89 0.021
Markers are divided by high versus low concentrations according to
median values
CI Confidence interval, HR Hazard ratio, ref. Referent, SAPS II Simplified Acute
Physiology Score II
Hansen et al. Critical Care  (2016) 20:40 Page 8 of 11
rather than instead of clinical assessment. This is in line
with previous studies investigating patients with sepsis
or septic shock that found PCT and CRP to have limited
abilities to predict outcome [36–38]. However, we found
that the AUC improved when the inflammatory markers
were combined. It may indicate that PTX3 in combin-
ation with other inflammatory markers can be used to
discern severe NSTI from milder courses in order to re-
fine the risk stratification. In particular, PTX3 level was
higher in patients needing amputation during the first
7 days in the ICU, whereas PCT and CRP were not.
Therefore, PTX3 might be used to identify the high-risk
patients who require aggressive surgery, while directing
a conservative approach to low-risk patients. The correl-
ation between PTX3 and SAPS II may also suggest that
PTX3 can be used as an easy assessment of disease se-
verity until SAPS II can be calculated or in cases where
SAPS II cannot be calculated due to missing values. An
explanation for the association between high PTX3 level
and increased disease severity and mortality may be
found in the biological action of PTX3 as it is released in
response to proinflammatory stimuli from interleukin-1
and tumor necrosis factor, thus potentially reflecting
higher bacterial loads. PTX3 also acts as a modulator of
the complement system, but a pathophysiological role re-
lated to tissue damage by amplifying the complement
pathways remains to be elucidated.
To our knowledge, this is one of the largest prospective
observational study cohorts of patients with NSTI and the
first study to investigate the prognostic value of PTX3 in
patients with NSTI. It is a strength that we managed to
include 98 % of all patients transferred to our center
where the treatment of NSTI has been centralized at a na-
tional level and that multiple measurements from each pa-
tients were obtained. Moreover, this study was based on
standardized sampling procedures ensured by using only a
few individuals as part of a 24-h on-call team with nine
members. Lastly, the external validity of the study results
is high due to few inclusion and exclusion criteria, thus in-
creasing the chance of the study cohort representing the
vast majority of patients with NSTI and making the results
applicable to daily clinical settings.
Several limitations must be considered. Firstly, the
study might be subject to potential bias as a conse-
quence of the inability to control for unknown con-
founders. Patients with NSTI represent a complex study
population as seen by the range and variance in age, mi-
crobiologic agents, site of infection and comorbidities,
thus making it difficult to isolate factors that potentially
affect the immunological response. Importantly, these
factors were not significantly different between patients
with septic shock and the other patients. Secondly, we
might have been able to minimize risk of observer and
detection bias if the individuals who reviewed the med-
ical records and did the statistical analyses had been
blinded. However, the staff performing the laboratory
analyses of PTX3, PCT and CRP were blinded to study
purpose and patient outcome. Thirdly, almost one out of
10 patients did not have sepsis according to the inter-
national criteria by Bone et al. [30] (Fig. 1). This rela-
tively large proportion might be explained by the fact
that most patients had to be transferred to our center to
be included. Some patients might have died before
transfer or might have been too hemodynamically un-
stable to be transferred, thereby increasing the risk of
selection bias. However, infections in critically ill patients
can also be present without any clinical manifestation of
the systemic inflammatory response syndrome [39], which
is confirmed in this study cohort. It is crucial that cli-
nicians know that patients with NSTI might not show
the classical signs of sepsis. Lastly, it would have been
interesting to have local PTX3 measurements from
the focus of infection and compare this with the released
amount in the blood stream. This could be incorporated
in future study protocols as it, to our knowledge, has not
been investigated before.
This study indicates that clinicians may consider
PTX3 as a marker of infection on equal terms with PCT
and that these markers are more reliable as prognostic
markers of disease severity than is CRP in patients with
NSTI. Additionally, these findings might be useful in
creating homogenous patient groups for future clinical
trials investigating NSTIs. It is important to note that
multiple analyses were conducted and that PCT and
CRP were secondary outcomes. This increases the risk
Fig. 4 Receiver operating characteristic curve of 180-day mortality in
patients with necrotizing soft tissue infections for the inflammatory
biomarkers. CRP C-reactive protein, PTX3 Pentraxin-3
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of chance findings. Even though we found associations
between PTX3 and clinical outcomes, the results should
be interpreted with caution. The prognostic and predictive
values need to be assessed in larger studies before PTX3
can be implemented in daily clinical practice. However,
the results imply a potential role for PTX3 in severity and
mortality prognostication in patients with NSTI.
Conclusions
We found that plasma PTX3 levels were associated with
septic shock, renal replacement therapy, amputation and
risk of death in patients with NSTI. However, PTX3 was
not an independent predictor of 180-day mortality.
Key messages
 The largest to date prospective, observational study
of patients with NSTI sampled over 25 months with
up to 2.5-year follow-up.
 It is of topical interest that we now have a new
inflammatory biomarker with a potential future role
in severity and mortality prognostication in patients
with NSTI.
 PTX3 level was higher in patients with NSTI
needing amputation, whereas PCT and CRP were not.
Therefore, PTX3 might be used to identify the high-
risk patients who require aggressive surgery, while
directing a conservative approach to low-risk patients.
 PTX3 is more reliable as a prognostic marker of
disease severity than PCT and CRP in patients with
NSTI.
 It is crucial that clinicians know that one out of 10
patients with NSTI might not show the classical
signs of sepsis.
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